Skip pattern approach toward the early access of innovative anticancer drugs

G. Apolone1, A. Ardizzoni2, A. Biondi3, A. Bortolami4, C. Cardone5, C. M. Ciniselli6, P. Conte7, C. Crippa8, F. de Braud9, M. Duca9, S. Gori10, G. Gritti11, A. Inno10, R. Luksch12, F. Lussana11, M. Maio13, G. Pasello14,15, F. Perrone16, A. Rambaldi17,18, G. Rossi19, D. Signorelli19, G. Soverini19, M. Valente13, P. Verderio6* & G. Buzzetti21

1Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; 2Department of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Policlinico Sant’Orsola-Malpighi, Bologna; 3Department of Pediatrics, University of Milano Bicocca—Fondazione MBBM/Ospedale San Gerardo, Monza; 4Reate Oncologica Veneta, Istituto Oncologico Veneto, Padova; 5Experimental Clinical Abdominal Oncology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli; 6Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; 7Istituto Oncologico Veneto, Padova; 8Department of Hematology, Spedali Civili di Brescia, Brescia; 9Department of Oncology and Haematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; 10Department of Oncology, IRCCS Sacro Cuore Don Calabria Hospital of Negrar, Verona; 11Hematology and Bone Marrow Transplantation Unit, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo; 12Department of Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; 13Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital of Siena, Siena; 14Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; 15Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova; 16Clinical Trials Unit, National Cancer Institute of Naples, Napoli; 17Department of Oncology-Hematology, University of Milan, Milano; 18Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo; 19Department of Hematology ASST Spedali Civili di Brescia, Brescia; 2059-7029/© 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Background: With the rapid development of innovative anticancer treatments, the optimization of tools able to accelerate the access of new drugs to the market by the regulatory authority is a major issue. The aim of the project was to propose a reliable methodological pathway for the assessment of clinical value of new therapeutic innovative options, to objectively identify drugs which deserve early access (EA) priority for solid and possibly in other cancer scenarios, such as the hematological ones.

Materials and methods: After a comprehensive review of the European Public Assessment Report of 21 drugs, to which innovation had previously been attributed by the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA), an expert panel formulated an algorithm for the balanced use of three parameters: Unmet Medical Need (UMN) according to AIFA criteria, Added Benefit (AB) according to the European Society for Medical Oncology’s Magnitude of Clinical Benefit Scale (ESMO-MCBS) criteria and Quality of Evidence (QE) assessed by the Grades of Recommendation Assessment, Development and Evaluation (GRADE) method. By sequentially combining the above indicators, a final priority status (i.e. EA or not) was obtained using the skip pattern approach (SPA).

Results: By applying the SPA to the non-curative setting in solid cancers, the EA status was obtained by 5 out of 14 investigated drugs (36%); by enhancing the role of some categories of the UMN, additional 4 drugs, for a total of 9 (64%), reached the EA status: 2 and 3 drugs were excluded for not achieving an adequate score according to AB and QE criteria, respectively. For hematological cancer, only the UMN criteria were found to be adequate.

Conclusions: The use of this model may represent a reliable tool for assessment available to the various stakeholders involved in the EA process and may help regulatory agencies in a more comprehensive and objective definition of new treatments’ value in these contexts. Its generalizability in other national contexts needs further evaluation.

Key words: early access priority, innovative anticancer treatments, unmet medical need, added benefit, quality of evidence

INTRODUCTION

Anticancer treatment options have rapidly increased in the past 20 years, with the introduction of targeted agents and immunotherapy in different cancer types. The optimization of the diagnostic pathway and the subsequent enrichment of the therapeutic armamentarium translate into survival improvement, accompanied by a rise in costs.1 Innovative drugs’ clinical use, following European Medicines Agency’s
(EMA) Committee for Medicinal Products for Human Use (CHMP) approval, has been a subject of debate for a long time. The Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) is the regulatory authority responsible for drug registration and access, working on behalf of the government for pharmaceutical expense monitoring and warranting a national consistency of the pharmaceutical system in agreement with regions. In this context, innovative drugs usually enter into a regulatory, bureaucratic and organizational ‘gray area’ until their real accessibility in all regions is granted. The time interval from the CHMP approval to the drug’s accessibility can sometimes reach up to 2 years, subtracting potentially improving or, more rarely, ‘game changing’ therapeutic options from a quick and extended clinical use, until the price and reimbursement negotiations between the marketing authorization holder and AIFA are completed.

Equal access to cancer care is one of the main goals for different stakeholders, though several challenges have been identified at each step of the process, from clinical trials to regulatory approval, up to national and regional pricing and reimbursement. A key challenge is represented by a reliable assessment of the clinical value and the cost-effectiveness of new therapeutic options, compared with the standard available care. Study design, efficacy and activity endpoints as well as patients’ follow-up or patient-reported outcomes should be collected during trials to support the level of evidence, which should also be considered in the drug development and approval path.

As far as solid tumors are concerned, the main scientific societies have proposed some tools to establish the clinical benefit of anticancer drugs, based on the added therapeutic value of each drug compared with control options in different settings. Particularly, the European Society for Medical Oncology’s Magnitude of Clinical Benefit Scale (ESMO-MCBS) was developed in 2015 and applied to each new drug or intervention approved by the EMA. This scale was applied both in curative and non-curative settings of most solid tumors and drugs with higher scores were considered for inclusion in ESMO guidelines. As regards the hematological area, a recent publication by Kiesewetter et al. describes a collaborative project between ESMO and the European Society of Hematology for the validation of ESMO-MCBS criteria in hematological malignancies. In 2017, AIFA identified the criteria for classification of innovative drugs focusing on therapeutic need, added therapeutic value and quality of evidence. While previous experience in other European countries explored the relationship between the added therapeutic value and price definition of anticancer drugs for solid tumors, no evidence is available on reproducible multi-parameter integrated criteria for early access (EA) priority classification of anticancer drugs both for solid and hematological tumors. Moreover, homogeneous criteria for the evaluation of clinical benefit are still not available for both solid oncology and hematology: the first being firmly anchored to the ESMO criteria, and the second currently lacking a similar methodological tool.

Starting from these premises, two Italian workshops involving a multidisciplinary expert panel addressed these issues. Specifically, the aim was to bring balanced and shared proposals to the attention of regulatory institutions, from a clinical, regulatory and health-economic point of view. In particular, the second workshop, held on 28-29 June 2018 in Villa Braida (Veneto) produced a preliminary publication, which raised the interest of some members of the AIFA Commission. The interest was focused not only on the specific EA area, but also on some in-depth analysis of the issues related to pharmaceutical innovation and its measurement, in case the current criteria will be revised in the future. Accordingly, a new project was set up to carry out a retrospective review of eligibility profiles for an EA ideal use of all the drugs that AIFA had considered innovative (and therefore authorized for clinical use and reimbursed through an ‘ad hoc innovation fund’) from March 2017 to September 2019.

The aim of the present paper is to propose simple and clear criteria, based on three parameters [unmet medical need (UMN), added benefit (AB) and quality of evidence (QE)], that, properly combined, could make the process of eligibility assessment as objective and reproducible as possible. The algorithm here proposed has been firstly applied in the non-curative solid oncology setting in order to evaluate its ability in defining the eligibility of innovative oncological cancer drugs for EA in Italy. This setting could be viewed as a template model to be adapted to both alternative scenarios, such as the hematological tumors, as well as in other European countries.

**MATERIALS AND METHODS**

**Study design**

The retrospective evaluation was carried out between July 2019 and May 2020 through the implementation of a working group. The latter consisted of nine medical oncologists (AA, ABi, CCa, MD, AI, RL, GP, DS, MV), four hematologists (CCr, GG, FL, GS) and one pharmacist (ABo) who evaluated the drugs/indications considered. In addition, two methodologists (GA, Gianluigi Casadei) and seven senior experts (PC, FdB, SG, MM, FP, AR, GR), who provided major contribution to the design of the study and supervised the data analysis and discussion, were involved. Thirty-one indications (Table 1) were selected referring to 21 drugs, to which the status of innovation had previously been attributed by AIFA: 22 indications were defined innovative according to the 2017 criteria (9 concerned onco-hematology and 13 solid cancer) and 9 according to previously defined criteria (4 concerned onco-hematology and 5 the oncology of solid tumors).

Data described in the European Public Assessment Report (EPAR) were taken as reference for each specific indication. Studies subsequent to the EPAR publication have not been evaluated, in order to line up with the knowledge available at the time of approval by the European agency (EMA).
Oncologists or hematologists evaluated in two independent review sections, the EPAR documentation or individual articles (when available) and expressed their judgment through an ad hoc designed case report form. In case of disagreement, a consensus value was achieved by collegial discussion also including the senior experts. A dedicated database was created using Microsoft Office Access 2007 (Microsoft Corporation, Redmond, WA).

**Data generation and analysis**

The process, applied to solid and hematological cancer indications, relied on the evaluation of the following three measurements: UMN, AB and QE. Table 2 reports the scales and relative categories for the three considered parameters. As regards the UMN, a five-point scale according to the 2017 AIFA criteria was adopted. Details about the scale are reported in Galeone et al. The AB evaluation was carried out according to the version 1.1 (v1.1) of the ESMO-MCBS criteria. Finally, for the QE parameter, the AIFA assessments for all indications considered innovative since 2017 were adopted. In addition, for indications considered innovative before 2017, QE was evaluated according to the GReFO (Regional Group of Oncological Drugs) of the Emilia Romagna region, based on the Grades of Recommendation Assessment, Development and Evaluation (GRADE) method. According to this scale, the quality of evidence can be scored as High (i.e. further research is very unlikely to change our confidence in the estimate of effect), Moderate (i.e. further research is likely to have an important impact on our confidence in the estimate of effect and

---

**Table 1. List of the considered indications**

| Indications defined innovative according to the 2017 criteria | Setting | RS-1 | RS-2 |
|-------------------------------------------------------------|---------|------|------|
| 01—Alectinib NSCLC ALK+ 1L                                  | Solid cancer | ABo, GP | MD, DS |
| 02—Daratumumab—MM 2 + L                                    | Onco-hematology | GG | CCr |
| 05—Pembrolizumab—NSCLC TPS50 1L                             | Solid cancer | ABo, GP | AA |
| 06—177Lu oxodotrotide—GEPNET                                | Solid cancer | AI | ABo, GP |
| 10—Dinutuzumab—neuroblastoma                               | Solid cancer | RL | ABI |
| 11—Midostaurin—AML FLT3+                                    | Onco-hematology | FL, AR | GS |
| 12—Atezolizumab NSCLC 2L                                    | Solid cancer | ABo, GP | AA |
| 13—Durvalumab NSCLC                                         | Solid cancer | ABo, GP | FP, CCA |
| 14—Tisagenlecleucel—RR LLA                                  | Onco-hematology | GG | GR |
| 15—Daunorubicin—Cytarabine—AML 1L                           | Onco-hematology | FL, AR | GS |
| 16—Alectinib NSCLC ALK 2L                                   | Solid cancer | ABo, GP | MD, DS |
| 17—Avelumab—MCC                                             | Solid cancer | FP, CCA | MM, MV |
| 18—Inotuzumab ozogamicin—ALL 2L                             | Onco-hematology | FL | AR |
| 20—Palbociclib—mBC HR+ HER2                                  | Solid cancer | AI | FP, CCA |
| 21—Ibrutinib—CLL 1L                                          | Onco-hematology | FL, AR | GS |
| 22—Ribociclib—mBC HR+ HER2                                  | Solid cancer | FP, CCA | MM, DS |
| 23—Nivolumab—RR cHL                                         | Onco-hematology | GG | CCr |
| 24—Lenalidomide—MM ASCT                                     | Onco-hematology | GG | CCr |
| 25—Regorafenib—HCC 2 + L                                    | Solid cancer | FP, CCA | MD, DS |
| 27—Niraparib—RCplatinio_responsivi                           | Solid cancer | FP, CCA | MD, DS |
| 28—Pembrolizumab—RR cHL                                     | Onco-hematology | GG | CCr |
| 29—Pembrolizumab—urothelal                                  | Solid cancer | AI | MM, MV |
| 03a—Ibrutinib—RR MCL CL                                      | Onco-hematology | GG | GS |
| 03b—Ibrutinib—WM                                             | Onco-hematology | GG | GS |
| 04a—Pembrolizumab—Melanoma advanced                         | Solid cancer | ABo, GP | MD, DS |
| 04b—Pembrolizumab—NSCLC TPS1 2L                             | Solid cancer | ABo, GP | MD, DS |
| 07—Nivolumab—Melanoma advanced                              | Solid cancer | FP, CCA | MD, DS |
| 08—Nivolumab—Melanoma advanced                              | Solid cancer | FP, CCA | MD, DS |
| 09—Nivolumab—RCC 2L                                         | Solid cancer | FP, CCA | GS |
| 19—Blinatumomab—RR LLA Ph—                                 | Onco-hematology | FL, AR | GS |
| 26—Venetoclax—CLL 17p-TPS3 2L                                | Onco-hematology | FL, AR | CCr |

| Indications defined innovative before the 2017 criteria       | Setting | RS-1 | RS-2 |
|-------------------------------------------------------------|---------|------|------|
| 03a—Ibrutinib—RR MCL CL                                      | Onco-hematology | GG | GS |
| 03b—Ibrutinib—WM                                             | Onco-hematology | GG | GS |
| 04a—Pembrolizumab—Melanoma advanced                         | Solid cancer | ABo, GP | MD, DS |
| 04b—Pembrolizumab—NSCLC TPS1 2L                             | Solid cancer | ABo, GP | MD, DS |
| 07—Nivolumab—Melanoma advanced                              | Solid cancer | FP, CCA | MD, DS |
| 08—Nivolumab—Melanoma advanced                              | Solid cancer | FP, CCA | MD, DS |
| 09—Nivolumab—RCC 2L                                         | Solid cancer | FP, CCA | GS |
| 19—Blinatumomab—RR LLA Ph—                                 | Onco-hematology | FL, AR | GS |
| 26—Venetoclax—CLL 17p-TPS3 2L                                | Onco-hematology | FL, AR | CCr |

**Table 2. Scales considered for the three parameters**

| Unmet medical need | Added benefit | Quality of evidence |
|--------------------|--------------|--------------------|
| High               | High         | High               |
| Important          | Important     | Important (4)      |
| Moderate           | Moderate (3)  | Moderate (3)       |
| Scarce             | Scarce (2)    | Scarce (2)         |
| Absent             | Absent (1)    | Absent (1)         |
| Scarce             | Scarce (2)    | Moderate (3)       |
| High               | High          | High               |
| Moderate           | Moderate      | Moderate           |
| Low                | Low           | Low                |
| Very Low           | Very Low      | Very Low           |

ALK, anaplastic lymphoma kinase; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ASCT, allogeneic autogeneic stem-cell transplantation; cHL, classical Hodgkin’s lymphoma; CCL, chronic lymphocytic leukemia; FLT3, FMS-like tyrosine kinase receptor-3; GEPNET, gastroenteropancreatic neuroendocrine tumor; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; mBC, metastatic breast cancer; MCC, metastatic Merkel cell carcinoma; MM, multiple myeloma; NSCLC, non-small-cell lung cancer; RCC, renal cell carcinoma; rOC, relapsed ovarian cancer; RR, relapsed/refractory; RS, review sections; TPS, tumor proportion score; WM, Waldenstrom macroglobulinemia.
may change the estimate), Low (i.e. further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate) and Very Low (i.e. any estimate of effect is very uncertain). In case of disagreement, a consensus value for each of the above parameters was reached by joint examination.

A simulation analysis was carried out by jointly considering the above three parameters in order to generate a priority score. Briefly, in this analysis, each $i$-th measurement ($i = 1, \ldots, 3$, where $1 = UMN$, $2 = AB$ and $3 = QE$) defines a decision level and each $j$-th category ($j = 1, \ldots, J$) of each measurement a decision rule (i.e. stop or pass). The process starts with the assignment of each considered measurement to a decision level and then proceeds with the definition of the decision rule for each measurement. The final output of this Skip Pattern Approach (SPA) consists of a priority status (i.e. EA or not) obtained by sequentially combining the considered measurement.

RESULTS

Solid oncology setting

Original skip pattern approach. Figure 1 shows the general scheme of the proposed SPA. Briefly, the UMN was the first-level measurement used to discriminate drugs needing further evaluation or not. Drugs with a ‘Scarce’ or ‘Absent’ score were immediately stopped, whereas those judged with at least a ‘Moderate’ score were further evaluated according to the AB. At this second level—where the AB was evaluated—drugs with a ‘Moderate’ UMN moved to the third level only if a ‘High’ score for the AB was achieved; else they were stopped. In the ‘High/Important’ arm of the UMN, only drugs with a ‘Scarce/Absent’ AB were stopped. At the third level—where the QE was evaluated—drugs were considered valid for ‘EA’ if a ‘High’ or ‘High/Moderate’ score was obtained.

According to the developed SPA, Table 3 reports the priority status (i.e. EA or not) for each of the 14 considered drugs, with 5 drugs out of 14 (36%, 95% confidence interval: 13% to 65%) in EA. Interestingly, no drugs were excluded at the first level (UMN), whereas five and four drugs were excluded at the second (AB) and third levels (QE), respectively.

Updated skip pattern approach. To enhance the role of some relevant categories of the AB and QE in the SPA, an updated algorithm was implemented by collapsing (i) for the AB, the ‘Important’ and the ‘High’ categories in the ‘Moderate’ UMN arm and (ii) for QE, the ‘Moderate’ category with the ‘High’ ones (Figure 2). In this case, at the second level—where the AB was evaluated—drugs with a ‘Moderate’ UMN moved to the third level also if an ‘Important’ score for the AB was achieved; else they were stopped. Similarly, at the third level—where the QE was evaluated—drugs were considered valid for ‘EA’ if a ‘High’ or ‘Moderate’ score was obtained in each flow arm. According to this updated SPA, four additional drugs moved to the EA status, for a total of nine drugs (64%; 95% confidence interval: 35% to 87%) (Table 4).

Hematological setting

Similar to the solid cancer setting, the working group carried out a thorough analysis of the abovementioned parameters. As regards the UMN, the criteria adopted by AIFA were

Figure 1. General scheme of the skip pattern approach.
Colored cells indicates the priority status and the exclusion level according to the general scheme of the skip pattern approach.
found to be adequate. On the other hand, as far as the AB is concerned, the use of the ESMO-MCBS v1.1 scale\(^5,6\) was considered not applicable in most indications, because it does not take into account the specific and particular aspects of hematological diseases. Moreover, as regards the assessment of the QE, the low number of randomized clinical trials (RCTs) strongly affects the evaluation of quality of evidence. In fact, >60% of analyzed studies were non-RCT, compared with the 27% in the solid oncology setting.

**DISCUSSION**

Constant and growing innovation in diagnostic and therapeutic pathways in oncology has rapidly raised the critical issue of a timely and extended access to new interventions able to improve survival and quality of life of cancer patients. Considering high disparities across European countries,\(^19\) the EMA established the PRIME (PRIority MEdicine) scheme for the optimization of regulatory tools, in order to prioritize innovative medicines addressing an unmet medical need and bringing a major potential therapeutic advantage to patients.\(^20\)

In Italy, as in other European countries, different regulatory tools for EA to innovative drugs are available, even though a comprehensive evaluation process of the new drug which takes into consideration the added value (compared with available options) and the place in therapy

---

**Table 3. Evaluation of the 14 indications according to the SPA**

| Indication | UMN     | AB         | QE          | Outcome     |
|-----------|---------|------------|-------------|-------------|
| 01—Alectinib NSCLC ALK+ 1L | Moderate | Important | Moderate | STOP        |
| 05—Pembrolizumab—NSCLC TPS50 1L | Moderate | Important | High | STOP        |
| 06—177Lu oxodotreotide—GEPNET | Important | Moderate | Low | STOP        |
| 10—Dinutuximab—Neuroblastoma | High | High | Moderate | STOP        |
| 12—Atezolizumab NSCLC 2L | Important | High | High | STOP        |
| 13—Durvalumab NSCLC | Important | Important | Moderate | STOP        |
| 16—Alectinib NSCLC ALK 2L | Moderate | Important | Moderate | STOP        |
| 17—Avelumab—MCC (setting naive) | Important | Moderate | Very Low | STOP        |
| 20—Palbociclib—mBC HR + HER2— | Moderate | Moderate | Moderate | STOP        |
| 22—Ribociclib—mBC HR + HER2— | Moderate | Moderate | Moderate | STOP        |
| 25—Regorafenib—HCC 2+L | High | Moderate | High | EARLY ACCESS |
| 27—Niraparib—rOC platino _responsivi | Important | Moderate | Moderate | STOP        |
| 29—Pembrolizumab—Urothelial | Important | High | EARLY ACCESS | EARLY ACCESS |

Colored cells indicates the priority status and the exclusion level according to the general scheme of the skip pattern approach (see Figure 1). AB, added benefit; ALK, anaplastic lymphoma kinase; GEPNET, gastroenteropancreatic neuroendocrine tumor; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; mBC, metastatic breast cancer; MCC, metastatic Merkel cell carcinoma; NSCLC, non-small-cell lung cancer; QE, quality of evidence; rOC, relapsed ovarian cancer; SPA, skip pattern approach; TPS, tumor proportion score; UMN, unmet medical need.

---

**Figure 2. General scheme of the updated skip pattern approach.**

Colored cells indicates the priority status and the exclusion level according to the updated scheme of the skip pattern approach.
in different settings is still lacking. A French experience reported the absence of correlation between the price of new cancer drugs and their added therapeutic benefit, as assessed by the French High Authority of Health and the ESMO-MCBS for drugs introduced in France between 2004 and 2017.

To our knowledge, this is the first effort proposing a reliable integrated algorithm for the classification of innovative drugs suitable for EA. Specifically, we simulated the process of assessment of the EA status for 14 indications in solid neoplasms by considering, as pivotal measurements, the UMN, AB and QE.

Some intriguing cues were derived from our results, warranting further discussion. Firstly, no drugs were excluded at the first level of the developed SPA algorithm, which was set as the UMN. We evaluated all the drugs and indications in the non-curative setting of solid tumors, and the reported UMN was always found to be moderate to high. Indeed, in this setting, we lack therapeutic options or, more often, there is only an availability of treatment options with no or limited impact on relevant outcome endpoints and/or with an unfavorable safety profile. An example is represented by the second-line treatment of metastatic non-oncogene-addicted non-small-cell lung cancer (NSCLC), where the immune programmed cell death protein 1/programmed death-ligand 1 (PD-L1) checkpoint inhibitors nivolumab, pembrolizumab and atezolizumab were assessed. The standard of care in this setting before the advent of immunotherapy was the chemotherapeutic agent docetaxel, showing modest survival outcomes and a poor safety profile, thus underlining the important clinical need in this setting.

The second and third levels of the SPA algorithm resulted in the exclusion of five and four drugs for the AB and QE, respectively, for a total of nine drugs. When the weight of some decision levels of these two measurements was enhanced in the updated SPA, four more indications moved to the EA. These findings further highlight the importance of a multidimensional evaluation of each new drug, in terms of endpoints reached, safety, quality of life, its setting and the scientific evidence supporting each treatment choice. Prospective studies should be carried out to eventually assess the SPA’s applicability, including the choice of the decision level for the AB and QE parameters in solid cancer.

In this context, where a moderate clinical need is shown, as in the first line setting of metastatic NSCLC, the clinical value of a drug, such as pembrolizumab in case of high PD-L1 expression, may make the difference in the path to EA, especially in case of high-quality evidence. Indeed, the clinical value of this drug within the specific setting has been graded as important, considering the primary endpoint of the pivotal phase III RCT, which was set as progression-free survival (PFS), as far as its added benefit to the available standard of care, safety and quality of life is concerned.

Moreover, a moderate quality of evidence should not preclude the EA of a drug in some contexts, especially when an important clinical need and a moderate clinical value are reported, as in platinum-sensitive relapsed ovarian cancer patients receiving maintenance niraparib.

One of the critical issues leading to a moderate quality of evidence is the availability of alternative drugs with the same mechanisms of action and the same indication, which makes the control arm not adequate. This is particularly true for small tyrosine kinase inhibitors, such as poly(ADP-ribose) polymerase inhibitors in ovarian cancer or anaplastic lymphoma kinase inhibitors in NSCLC, where the quality of evidence supporting a ‘next in class’ may be affected. In general, the central role of the clinical need would deserve a discussion with regulatory agencies (e.g. AIFA) and the technical—scientific committee about the role of the new therapeutic alternatives, because they could be affected in terms of innovation and EA.

For the hematological area, it was not possible to apply the SPA approach due to difficulties in assessing AB and QE. As regards the AB, the difficulties were mainly related to the

### Table 4. Evaluation of the 14 indications according to the updated SPA

| Indication | UMN | AB   | QE   | Output       |
|------------|-----|------|------|--------------|
| 01—Alectinib NSCLC ALK + 1L | Moderate | Important | Moderate | EARLY ACCESS |
| 05—Pembrolizumab—NSCLC TPS50 1L | Moderate | Important | High | EARLY ACCESS |
| 06—177Lu oxodotreotide—GEPNET | Important | Moderate | Low | STOP |
| 10—Dinutuximab—Neuroblastoma | High | Moderate | Low | STOP |
| 12—Atezolizumab NSCLC 2L | Important | High | High | EARLY ACCESS |
| 13—Durvalumab NSCLC | Important | Important | Moderate | EARLY ACCESS |
| 16—Alectinib NSCLC ALK 2L | Moderate | Important | Moderate | EARLY ACCESS |
| 17—Avelumab—MCC (setting naive) | Important | Moderate | Low | STOP |
| 17—Avelumab—MCC (setting refrattario) | Important | Moderate | Low | STOP |
| 20—Pallbocibloc—mBC HR + HER2— | Moderate | Important | Moderate | EARLY ACCESS |
| 22—Ribociclib—mBC HR + HER2— | Moderate | Moderate | Moderate | STOP |
| 25—Regorafenib—HCC 2 + L | High | Moderate | High | STOP |
| 27—Niraparib—rOC platino _responsivi | Important | Moderate | Moderate | EARLY ACCESS |
| 29—Pembrolizumab—Urotheial | Important | Moderate | High | EARLY ACCESS |

The drugs moved to the early access status according to the updated SPA are given in bold. Colored cells indicate the priority status and the exclusion level according to the updated scheme of the skip pattern approach (see Figure 2).

AB, added benefit; ALK, anaplastic lymphoma kinase; GEPNET, gastroenteropancreatic neuroendocrine tumor; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; mBC, metastatic breast cancer; MCC, metastatic Merkel cell carcinoma; NSCLC, non-small-cell lung cancer; QE, quality of evidence; rOC, relapsed ovarian cancer; SPA, skip pattern approach; TPS, tumor proportion score; UMN, unmet medical need.
behavior of hematological malignancies, the survival outcomes and relative metrics used in hematology and the existence of single-arm trials only. Hematological diseases include rapidly fatal but also curable tumors, such as acute leukemia and chronic forms characterized by very long survival time, although still definable as incurable (such as chronic lymphocytic leukemia). In some hematological diseases, treatments have curative intent and generate survival curves with plateaus, where the evaluation of the AB on survival may be carried out more efficiently using alternative parameters (like the restricted mean survival time).29 In addition, the endpoints used in hematology are sometimes different from those commonly used in solid oncology. For example, in some diseases and/or for some ‘precision drugs’ with a specific immunological or molecular target, response is assessed in terms of measurable residual disease negativity. Accordingly, the introduction of proper predictive metrics could be of help in evaluating such setting. With regard to QE, the rarity of many diseases may explain a difficulty in performing RCT and consequently in providing a suitable QE assessment.

Despite the abovementioned limitations, during the working group discussions, the potential role of the SPA approach emerged even in the hematological setting. To this end, the AIFA assessments of UMN could be integrated with the AB assessment using a validated ESMO-MCBS version developed for hematological malignancies, such as that recently suggested by ESMO and the European Hematology Association.6

We believe that the strength of our study concerns the scales adopted for the three considered measurements; indeed, both ESMO and AIFA metrics are validated tools already used by clinicians and regulators in different contexts of drug development process. A further strength of our experience consists in the availability of measurements reached after a consensus discussion, in case of a judgment disagreement. This supports the need for establishing a multidisciplinary expert panel, which leads, in our case, to a validation of the EA in 60% of the assessed indications. Regarding the study limitations, these are mainly related to the retrospective review of the analysis, which should be prospectively validated. Moreover, the developed SPA does not cover other regulatory aspects such as those related to the subsequent negotiation—reimbursement process, based on parameters which are difficult to put under control and homogenize. However, it could be viewed as a pilot experience in developing a structured approach for the decision-making process granting an EA to innovative anticancer drugs. Study design, efficacy and activity endpoints as well as patients’ follow-up or patient-reported outcomes should be collected during trials to support the level of evidence, which should also be considered in the drug development and approval path. Finally, it should be considered, as published recently,30 that methodological aspects related to trial design and statistical analysis can affect the trial’s interpretation and conclusions. Such methodological aspects should be taken into account during the appraisal process of innovative drugs.

In conclusion, this model represents a step toward a consensus between several stakeholders involved in the EA process. Coherently, the considered setting can be viewed as a template model to be opportunistically evaluated to both alternative scenarios, such as the hematological tumors, as well as in other European countries to eventually assess its generalizability. In the near future, as regulatory agencies and scientific committee will be called to assess new drugs with longer survival outcomes, surrogate endpoints such as PFS in solid tumors and minimal residual disease should be opportunistically considered within the regulatory framework of innovative drugs.

ACKNOWLEDGEMENTS

We thank Gianluigi Casadei for the project’s methodology definition and supervision and Irene Marzona for the editorial support.

FUNDING

Depharmaforum S.r.l., funded the entire project (no grant number).

DISCLOSURE

AA reports grants and personal fees from BMS, and grants from MSD, Roche, AstraZeneca, Eli Lilly, Takeda and Bayer, outside the submitted work. ABI reports fees for advisory board from Novartis, Amgen and Colnmune, and research grant from Colnmune. FdB has received honoraria or consultation fees for consultant advisory board from TizianaLife Sciences, BMS, Novartis, Pharm Research Associated, Daichi Sankyo, Ignyta, Amgen, Pfizer, Octimet Oncology, Incyte, Teofarma, Pierre Fabre, Roche, EMD Serono, Sanofi and NMS Nerviano Medical Science, and as speaker from BMS, Eli Lilly, Roche, Amgen, AstraZeneca, Fondazione Menarini, Novartis, MSD, Ignyta, Bayer, ACCMED, Depharmaforum S.r.l., Nadirex, Merc Merck, Biotechspert Ltd, PriME Oncology, Pfizer, Servier, Celgene, Tesaro, Loxo Oncology Inc. and Sanofi. GG reports fees as consultant or participant to advisory board from Takeda, IQvia and Gilead Sciences; honoraria from Amgen and Roche; research funding from Gilead Sciences; and travel grants from Roche, Abbvie and Gilead Sciences, outside the submitted work. RL reports personal fees for advisory board or sponsored lectures from Amgen, Pfizer, Astellas, Jazz Pharmaceuticals and Janssen. MM has received honoraria or consultation fees from Roche, MSD, BMS, AstraZeneca, Astex, GSK, Amgen, Incyte, Pierre Fabre, Merck Serono, Eli Lilly, Sanofi, Scilicone, Alfasigma and Epigen Therapeutics, and owns shares of Theravance and Epigen Therapeutics. GP serves as an advisor/consultant for MSD, BMS, Lilly, Boehringer Ing, Roche, AstraZeneca and Novartis. FP reports personal fees from Astellas, AstraZeneca, Bayer, Clovis, Incyte, Ipsen, Pierre Fabre, Roche and Sanofi for educational or advisory role outside the submitted work. AR reports personal fees for advisory board or sponsored lectures from Celgene, BMS, Sanofi, Novartis, Italfarmaco, Amgen, Pfizer, Kite...
Gilead, Astellas, Jazz and Omeros. GR reports personal fees for advisory board from Abbvie, Janssen, Sanofi, Amgen, Pfizer, Astellas, Jazz and Daiichi Sankyo. DS reports personal fees form AstraZeneca, MSD, Boehringer Ingelheim, BMS and Eli Lilly outside the submitted work. All other authors have declared no conflicts of interest.

REFERENCES

1. The IQVIA Institute. Global Oncology Trends 2017: Advances, Complexity and Cost. 2017. Available at https://www.iqvia.com/institute/reports/global-oncology-trends-2017-advances-complexity-and-cost. Accessed July 26, 2021.
2. Russo P, Mennini FS, Siviero PD, Rasi G. Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. Ann Oncol. 2010;21:2081-2087.
3. Wilking N, Bucsis A, Randolf Sekulovic L, et al. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries. ESMO Open. 2019;4:e000550.
4. Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26:1547-1573.
5. Cherny NI, de Vries EGE, Dafni U, et al. Comparative assessment of clinical benefit using the ESMO-Magnitude of Clinical Benefit Scale version 1.1 and the ASCO Value Framework Net Health Benefit Score. J Clin Oncol. 2019;37:336-349.
6. Kiesewetter B, Cherny NI, Boissel N, et al. EHA Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open. 2020;5:e000611.
7. Fondazione GIMBE. Determina AIFA per la classificazione di farmaci innovativi e dei farmaci oncologici innovativi ai sensi dell’articolo 1, comma 420, della legge 11 dicembre 2016, n. 232 (Determina n. 519/2017).
8. Galeone C, Bruzi P, Iommi C. Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system. BMJ Open. 2021;11(1):e041259.
9. Aifa—Italian Medicines Agency Working Group on Innovative Drugs. Criteria for ranking therapeutic innovation of new drugs and elements for supplementing the dossier for admission to the reimbursement system. Available at http://www.agenziafarmaco.gov.it/allegati/integral_document.pdf. Accessed July 26, 2021.
10. Criteri per la classificazione dei farmaci innovativi e dei farmaci oncologici innovativi ai sensi dell’articolo 1, comma 420, della legge 11 dicembre 2016, n. 232 (Determina n. 519/2017).
11. Rodwin MA, Mancini J, Duran S, et al. The use of “added benefit” to determine the price of new anti-cancer drugs in France, 2004–2017. Eur J Cancer. 2021;145:11-18.
12. Apolone G, Ardiszoni A, Buzzetti G, et al. Early access in oncology: why is it needed? Glob Reg Health Technol Assess. 2019;2019:1-7.
13. Criteri per la classificazione dei farmaci innovativi, e dei farmaci oncologici innovativi, ai sensi dell’articolo 1, comma 420 della legge 11 dicembre 2016, n. 232 (Determina n.1535/2017).
14. European Medicines Agency. Medicines. Available at https://www.ema.europa.eu/en/medicines. Accessed July 26, 2021.
15. AIFA. Innovative medicinal products. Available at https://www.aifa.gov.it/eqs/ptr/elaborati. Accessed July 26, 2021.
16. Cherny NI, Dafni U, Bogaerts J, et al. E.G.E. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28:2340-2366.
17. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
18. Prontuaria terapeutico regionale (per data di approvazione). Available at https://salute.regione.emilia-romagna.it/srr/strumenti-e-infozioni/prtr/elaborati. Accessed July 26, 2021.
19. Jönsson B, Hofmarcher T, Lindgren P, Moen F, Wilking N. Comparator Report on Patient Access to Cancer Medicines in Europe Revisited—A UK Perspective (IHE report; No. 2017:1). IHE, Institutet för hälso- och sjukvårdssekonomi. 2017. Available at https://www.abpi.org.uk/media/3459/report-access-cancer-medicines-in-europe-revisited-uk-perspective.pdf. Accessed July 26, 2021.
20. European Medicines Agency. Two years of PRIME. Available at https://www.ema.europa.eu/en/news/two-years-prime. Accessed July 26, 2021.
21. Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39:723-733.
22. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540-1550.
23. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-265.
24. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18:2354-2362.
25. Rodríguez-Abreu D, Powell SF, Hochmair MJ, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32:881-895.
26. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol. 2021. https://doi.org/10.1200/JCO.21.00174.
27. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-1833.
28. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154-2164.
29. Uno H, Caggett B, Tian L, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014;32:2380-2385.
30. Gyawali B, de Vries EGE, Dafni U, et al. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. ESMO Open. 2021;6:100117.